Financial Result for quarter and year ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025. Consolidated FY25 revenue jumped sharply to Rs 10,980.34 lakhs (vs Rs 3,723.86 lakhs in FY24), but the company swung to a consolidated net loss of Rs 132.22 lakhs from a Rs 92.50 lakh profit a year ago. Standalone revenue actually declined to Rs 2,285.31 lakhs with a net loss of Rs 119.58 lakhs. The revenue surge was largely driven by newly acquired subsidiary Trinity Ganesh Pvt Ltd (acquired Feb 7, 2025), which contributed Rs 8,682.13 lakhs. Operating cash flow remained negative at Rs (538.29) lakhs consolidated and trade receivables/payables ballooned sharply. Other board decisions include approval to acquire a 35% stake in Angolan pharma firm Angav Indústria Farmacêutica S.A., sale of ~6.25 Bigha land at Sanand (no impact on operations), appointment of new internal and secretarial auditors, and noted the resignation of Company Secretary Ms. Vinita Keswani.
The headline revenue growth is acquisition-led rather than organic, and the swing to losses with persistent negative operating cash flow signals weak earnings quality – shareholders should track subsidiary margins, receivable collection, and the execution of the Angola foray. The land sale and auditor changes are routine, while the Angola investment adds long-term but uncertain optionality.